Explore the Agenda
9:00 am Registration & Coffee
9:30 Workshop A
Advancing Outcomes-Based Reimbursement to Secure Sustainable Access for Cell & Gene Therapies
As next generation gene and cell therapies enter the market, outcomes-based reimbursement is emerging as a critical tool to align pricing with demonstrated clinical benefit. However, manufacturers continue to face significant challenges, from defining meaningful outcome measures to navigating payer expectations and evolving policy frameworks. This workshop offers a focused, strategic deep dive into how innovators can design feasible outcomes-based reimbursement models that build payer confidence and support sustainable patient access.
This workshop will gather experts to discuss:
- Understanding the strategic role of outcomes-based reimbursement in enabling timely access to high-cost advanced therapies
- Strengthening the data foundations and evidence required to engage effectively with payers
- Defining outcomes that are measurable, clinically meaningful, and operationally feasible to track
- Exploring operational challenges related to data collection, durability assessment, and real-world evidence generation
12:30 pm Lunch Break & Networking
13:30 Workshop B
Communicating the Value of Advanced Therapies to Build Stakeholder Confidence & Support Sustainable Access
Cell and gene therapies offer transformative clinical potential but introduce unique pricing and reimbursement challenges that can delay or restrict patient access. Payers must evaluate therapies characterized by high upfront costs, limited long-term durability data at launch, and small patient populations. Short budget cycles, member churn, reinsurance considerations, public payer constraints, and evolving evidence standards further complicate value assessment and coverage decisions. Treatment centers also face operational and reimbursement risk when delivering high-cost advanced therapies. This workshop provides a practical forum to explore how manufacturers can communicate value credibly, address budget impact concerns, and prepare for real-world reimbursement decision making.
This workshop will gather experts to discuss:
- How to communicate long term clinical and economic value for advanced therapies within payer budget cycles that may span only two to three years
- Framing high upfront costs in ways that strengthen payer confidence despite uncertainty around durability and limited real-world evidence
- Understand how to communicate value to treatment centers managing operational, reimbursement, and site-of-care financial risk when delivering high-cost therapies
- Equip commercial and access teams to support healthcare centres in navigating process bottlenecks such as financial clearance, prior authorization, and revenue cycle risk